ScholarIQanswers from OpenAlex & ORCID
Stephen D. Silberstein
ResearcherPublications, citations & collaboration network
Stephen D. Silberstein is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stephen D. Silberstein have?
ScholarIQindexed works
Stephen D. Silberstein has 662 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stephen D. Silberstein have?
ScholarIQcitation count
Stephen D. Silberstein has 38,207 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stephen D. Silberstein?
ScholarIQh-index
Stephen D. Silberstein has an h-index of 101 in OpenAlex.
What is the i10-index of Stephen D. Silberstein?
ScholarIQi10-index
Stephen D. Silberstein has an i10-index of 346 in OpenAlex.
What is the OpenAlex record for Stephen D. Silberstein?
ScholarIQopenalex
The OpenAlex for Stephen D. Silberstein is on the source record.
What are the most-cited papers on Stephen D. Silberstein?
ScholarIQmost cited works
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program
David W. Dodick, Catherine C. Turkel, Ronald E. DeGryse, Sheena K. Aurora, Stephen D. Silberstein, Richard B. Lipton, Hans‐Christoph Diener, Mitchell F. Brin
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein, David W. Dodick, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart J. Tepper, Messoud Ashina, Uwe Reuter, Jan Lewis Brandes, David Doležil, Stephen D. Silberstein, Paul Winner, Dean Leonardi, Daniel D. Mikol, Robert Lenz
Cutaneous allodynia in the migraine population
Richard B. Lipton, Marcelo E. Bigal, Sait Ashina, Rami Burstein, Stephen D. Silberstein, Michael L. Reed, Daniel Serrano, Walter F. Stewart, American Migraine Prevalence Prevention Advisory Group
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
David W. Dodick, Stephen D. Silberstein, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi